Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
Recruiting · NCT07053982 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Toulouse
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. \[18F\]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of \[18F\]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.
Who can take part
Inclusion criteria
- Cases:
- \- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;
- Controls:
- Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility;
- Age \> 18 years;
- Patient who provided informed consent;
- Patients who underwent a preoperative MRI and were not contraindicated for \[18F\]-FES PET/CT;
- Patient who underwent surgery mid-cycle;
- Affiliation to a social security scheme
Exclusion criteria
- Patient treated for endometriosis without surgery;
- Pregnant patient
- Patient taking hormone therapy
- Menopausal patient
- Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients
- Patient under legal protection
- Claustrophobic patient
Where it is running
1 location listed.
- Toulouse, Rangueil Hospital - Toulouse, France